Cipher Pharmaceuticals is a rapidly growing specialty pharmaceutical dermatology company, with a robust and diversified portfolio of commercial and late-stage products. Cipher acquires first-in-class or best-in-class products and transformative compounds that fulfill high unmet medical needs. Our experienced management team has a proven track record of successfully managing the required clinical development and regulatory approval processes and marketing products either directly or through partners. Cipher is well-capitalized to drive sustained earnings growth by leveraging our proven clinical development capabilities and efficient commercial execution. With seven transactions announced in 2015, we are on pace to achieve our goal of expanding our Canadian dermatology franchise, building a U.S. commercial presence and ultimately, becoming the most customer-centric dermatology company in North America.
CIPHER PHARMACEUTICALS ANNOUNCES PLANS TO VOLUNTARILY DELIST FROM NASDAQ
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources
Receive E-mail Alerts|
|Sign up to receive e-mail alerts whenever Cipher Pharmaceuticals Inc posts new information to the site. Just enter your e-mail address and click Submit.|